| abstract |
The present disclosure comprises an ophthalmic formulation comprising one or more pharmaceutically acceptable excipients, pharmaceutically active compounds capable of reducing the amount or adverse effects of autoantibodies on the ocular surface such as IgG. offer. In particular, in the present disclosure, pharmaceutically active compounds include eye discomfort, keratitis, dry eye disease, symblepharon formation, fornix forestering, limbal margin / conjunctival keratoma. For ophthalmology that can treat clinical conditions selected from the group consisting of inflammatory, infectious and immunological ocular surface or intraocular disorders that can cause symptoms of symblepharon, subconjunctival fibrosis, retinal gliosis and glaucoma. Provide formulation. |